{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:38:57Z","timestamp":1793093937849,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00927-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T18:56:02Z","timestamp":1745261762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaomei","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taomin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"4","key":"927_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","volume":"40","author":"RJ Casson","year":"2012","unstructured":"Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012;40(4):341\u201349.","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"927_CR2","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"JDBRBP Steinmetz","year":"2021","unstructured":"Steinmetz JDBRBP. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to vision 2020: the right to sight: an analysis for the global burden of disease study. Lancet Glob Health. 2021;9(2):e144\u201360.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"927_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"issue":"1","key":"927_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BJ Prum","year":"2016","unstructured":"Prum BJ, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary open-angle glaucoma preferred practice pattern(\u00ae) guidelines. Ophthalmology. 2016;123(1):41\u2013111.","journal-title":"Ophthalmology"},{"key":"927_CR5","doi-asserted-by":"crossref","unstructured":"Dasso L, Al-Khaled T, Sonty S, Aref AA. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. 2018:1939\u201344.","DOI":"10.2147\/OPTH.S154001"},{"issue":"14","key":"927_CR6","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"57","author":"R Ren","year":"2016","unstructured":"Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57(14):6197\u2013209.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"927_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (Rocket-1 and Rocket-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"927_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, Kim T, Raizman MB, Heah T, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho kinase elevated Iop treatment trial (Rocket-2). Am J Ophthalmol. 2019;200:130\u201337.","journal-title":"Am J Ophthalmol"},{"key":"927_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 Rocket-4 study. Am J Ophthalmol. 2019;204:97\u2013104.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"927_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1097\/IJG.0000000000001634","volume":"29","author":"IP Singh","year":"2020","unstructured":"Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29(10):878\u201384.","journal-title":"J Glaucoma"},{"issue":"11","key":"927_CR11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.ophtha.2018.08.004","volume":"125","author":"MM Fernandez","year":"2018","unstructured":"Fernandez MM. Reticular epithelial edema in edematous Corneas treated with netarsudil. Ophthalmology. 2018;125(11):1709.","journal-title":"Ophthalmology"},{"issue":"4","key":"927_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4103\/ijo.IJO_2865_21","volume":"70","author":"M Bhargava","year":"2022","unstructured":"Bhargava M, Sen S, Bhambhani V, Paul RS, Dutta C. Reticular epithelial corneal edema as a novel side-effect of Rho kinase inhibitors: an Indian scenario. Indian J Ophthalmol. 2022;70(4):1163\u201370.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"927_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/ICO.0000000000002621","volume":"40","author":"SA LoBue","year":"2021","unstructured":"LoBue SA, Moustafa GA, Vu A, Amin M, Nguyen T, Goyal H. Transient reticular cystic corneal epithelial edema with topical Netarsudil: a case series and review. Cornea. 2021;40(8):1048\u201354.","journal-title":"Cornea"},{"key":"927_CR14","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.ajoc.2020.100800","volume":"19","author":"MS Ramakrishnan","year":"2020","unstructured":"Ramakrishnan MS, Addis VM, Lehman AY, Sankar PS. Netarsudil-associated epithelial keratopathy. Am J Ophthalmol Case Rep. 2020;19:100800.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"927_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ajo.2020.04.002","volume":"217","author":"CE Wisely","year":"2020","unstructured":"Wisely CE, Liu KC, Gupta D, Carlson AN, Asrani SG, Kim T. Reticular bullous epithelial edema in Corneas treated with Netarsudil: a case series. Am J Ophthalmol. 2020;217:20\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"18","key":"927_CR16","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1038\/s41433-024-03342-4","volume":"38","author":"JB Lin","year":"2024","unstructured":"Lin JB, Harris JM, Baldwin G, Goss D, Margeta MA. Ocular effects of Rho kinase (ROCK) Inhibition: a systematic review. Eye (Lond). 2024;38(18):3418\u201328.","journal-title":"Eye (Lond)"},{"issue":"6","key":"927_CR17","first-page":"D13817","volume":"6","author":"FJ Clement","year":"2022","unstructured":"Clement FJ, von Spreckelsen A, Kolko M, Azuara-Blanco A, Virgili G. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022;6(6):D13817.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"927_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/ceo.14224","volume":"51","author":"R Karri","year":"2023","unstructured":"Karri R, Chong EW. Rock inhibitors in ophthalmology: a critical review of the existing clinical evidence. Clin Exp Ophthalmol. 2023;51(5):472\u201383.","journal-title":"Clin Exp Ophthalmol"},{"issue":"11","key":"927_CR19","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R Bohm","year":"2021","unstructured":"Bohm R, Bulin C, Waetzig V, Cascorbi I, Klein HJ, Herdegen T. Pharmacovigilance-based drug repurposing: the search for inverse signals via openvigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol. 2021;87(11):4421\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"927_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/14740338.2024.2322712","volume":"23","author":"X Xiong","year":"2024","unstructured":"Xiong X, Zhang X, Li X, Huang T. Adverse events associated with Brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf. 2024;23(11):1447\u201352.","journal-title":"Expert Opin Drug Saf"},{"key":"927_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.exer.2016.08.023","volume":"158","author":"PV Rao","year":"2017","unstructured":"Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho Gtpase\/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res. 2017;158:23\u201332.","journal-title":"Exp Eye Res"},{"key":"927_CR22","doi-asserted-by":"publisher","first-page":"101287","DOI":"10.1016\/j.ajoc.2022.101287","volume":"25","author":"JA Tran","year":"2022","unstructured":"Tran JA, Jurkunas UV, Yin J, Davies EC, Sola-Del VD, Chen TC, et al. Netarsudil-associated reticular corneal epithelial edema. Am J Ophthalmol Case Rep. 2022;25:101287.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"927_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/APO.0000000000000553","volume":"12","author":"K Mandlik","year":"2023","unstructured":"Mandlik K, Christy SJ, Ravisankar R. Netarsudil-induced honeycomb hypertrophy. Asia Pac J Ophthalmol (Phila). 2023;12(5):504\u201305.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"8","key":"927_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5693\/djo.02.2022.02.002","volume":"28","author":"LJ Jeang","year":"2022","unstructured":"Jeang LJ, Shah AS, Hammer JD, Tuli SS. Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil. Digit J Ophthalmol. 2022;28(8):34\u20137.","journal-title":"Digit J Ophthalmol"},{"issue":"1","key":"927_CR25","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, et al. One-year clinical evaluation of 0.4% Ripasudil (k-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26\u201334.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"927_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12886-020-01490-1","volume":"20","author":"H Tanihara","year":"2020","unstructured":"Tanihara H, Kakuda T, Sano T, Kanno T, Gunji R. Safety and efficacy of Ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of rock-j, a post-marketing surveillance study. Bmc Ophthalmol. 2020;20(1):275.","journal-title":"Bmc Ophthalmol"},{"issue":"7","key":"927_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ophtha.2022.02.025","volume":"129","author":"TM Meirick","year":"2022","unstructured":"Meirick TM, Mudumbai RC, Zhang MM, Chen PP. Punctal stenosis associated with topical netarsudil use. Ophthalmology. 2022;129(7):765\u201370.","journal-title":"Ophthalmology"},{"issue":"11","key":"927_CR28","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/IJG.0000000000002124","volume":"31","author":"R Rashad","year":"2022","unstructured":"Rashad R, Zhu C, Kupcha AC, Distefano AG, Kefella H, Desai MA. Partial stenosis and complete punctal closure following topical netarsudil use for glaucoma. J Glaucoma. 2022;31(11):920\u201325.","journal-title":"J Glaucoma"},{"issue":"4","key":"927_CR29","first-page":"270","volume":"4","author":"F Pakdel","year":"2009","unstructured":"Pakdel F, Bahmani KM. Lacrimal drainage obstruction associated with topical and systemic medications. J Ophthalmic Vis Res. 2009;4(4):270\u201371.","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"927_CR30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00417-019-04514-9","volume":"258","author":"JK Jang","year":"2020","unstructured":"Jang JK, Lee SM, Lew H. A histopathological study of lacrimal puncta in patients with primary punctal stenosis. Graefes Arch Clin Exp Ophthalmol. 2020;258(1):201\u201307.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"927_CR31","doi-asserted-by":"publisher","first-page":"101501","DOI":"10.1016\/j.ajoc.2022.101501","volume":"26","author":"D Chung","year":"2022","unstructured":"Chung D, Meier EJ. Rapid and reversible alteration in corneal contour and power associated with Netarsudil\/latanoprost. Am J Ophthalmol Case Rep. 2022;26:101501.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"927_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000524362","volume":"13","author":"D Ganesh","year":"2022","unstructured":"Ganesh D, Coleman AL, Shibayama VP, Tseng VL. Netarsudil-induced corneal flattening in a child with secondary open-angle glaucoma. Case Rep Ophthalmol. 2022;13(2):330\u201335.","journal-title":"Case Rep Ophthalmol"},{"issue":"5","key":"927_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ogla.2020.04.011","volume":"3","author":"S Asanad","year":"2020","unstructured":"Asanad S, Zhang R, Saeedi OJ. Corneal hemorrhage associated with netarsudil in the setting of corneal neovascularization. Ophthalmol Glaucoma. 2020;3(5):392.","journal-title":"Ophthalmol Glaucoma"},{"key":"927_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08164622.2024.2400322","volume":"12","author":"T Sood","year":"2024","unstructured":"Sood T, Chahuan N, Shree A. Corneal vascularisation and haemorrhage associated with netarsudil drops. Clin Exp Optom. 2024;12:1\u20132.","journal-title":"Clin Exp Optom"},{"issue":"5","key":"927_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajo.2015.01.026","volume":"159","author":"B Levy","year":"2015","unstructured":"Levy B, Ramirez N, Novack GD, Kopczynski C. Ocular hypotensive safety and systemic absorption of ar-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159(5):980\u201385.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"927_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/IJG.0000000000001956","volume":"31","author":"EL Chang","year":"2022","unstructured":"Chang EL, Emmel DK, Teng CC, Sarrafpour S, Liu J. Anterior subcapsular cataract formation with long-term topical netarsudil treatment for glaucoma. J Glaucoma. 2022;31(1):60\u20133.","journal-title":"J Glaucoma"},{"issue":"5","key":"927_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. A systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"9","key":"927_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2165\/00002018-200528090-00007","volume":"28","author":"MT Herdeiro","year":"2005","unstructured":"Herdeiro MT, Figueiras A, Pol\u00f3nia J, Gestal-Otero JJ. Physicians\u2019 attitudes and adverse drug reaction reporting. Drug Saf. 2005;28(9):825\u201333.","journal-title":"Drug Saf"},{"issue":"9\u201310","key":"927_CR39","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s002280000202","volume":"56","author":"M B\u00e4ckstr\u00f6m","year":"2000","unstructured":"B\u00e4ckstr\u00f6m M, Mj\u00f6rndal T, Dahlqvist R, Nordkvist-Olsson T. Attitudes to reporting adverse drug reactions in Northern Sweden. Eur J Clin Pharmacol. 2000;56(9\u201310):729\u201332.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"927_CR40","first-page":"1015","volume":"10","author":"A Sandberg","year":"2022","unstructured":"Sandberg A, Salminen V, Heinonen S, Siv\u00e9n M. Under-reporting of adverse drug reactions in Finland and healthcare professionals\u2019 perspectives on how to improve reporting. Healthc (Basel). 2022;10(6):1015.","journal-title":"Healthc (Basel)"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00927-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T18:56:04Z","timestamp":1745261764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00927-x","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent to participate was not needed for this study because FAERS is a public anonymized database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}